Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE) conference in Barcelona, Spain on November 14-16, 2022.

W. Frank An, Ph.D., Senior Director of Antibody Therapeutics at Biocytogen, will give an oral presentation at 13:50-14:20 on Tuesday, November 15, introducing Biocytogen’s proprietary fully human common light chain antibody platform (RenLite^®) and its applications for correct heavy chain and light chain pairing during development of bispecific antibodies (BsAbs) and bispecific antibody-drug conjugates (BsADCs).

In addition, Biocytogen will present 3 posters introducing the latest progress of YH013 (EGFR x MET BsADC), 1C3 (anti-TNFR2 monoclonal antibody), and Biocytogen’s TCR-mimic antibody platform.

Details of our presentations are as follows:

Monday, November 14:

Poster A5：1C3, a Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy

Poster A6：A Novel TCR-mimic Fully Human Antibody Discovery Platform

Tuesday, November 15:

Oral Presentation: Innovative Bispecific Therapeutic Antibody Discovery with the RenLite Fully Human Common Light Chain Antibody Platform

Poster B6：YH013, a Fully-Human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-Tumor Efficacy

Biocytogen welcomes licensing and co-development inquiries. Interested parties may contact us at BD-Licensing@biocytogen.com to set up a meeting.

Click here to read the abstract of our oral presentation and view the conference schedule.

Click here to view the complete schedule for poster presentations.